Most smaller biotech companies would love to follow in the footsteps of Vertex Pharmaceuticals (NASDAQ: VRTX). The company is the global leader in cystic fibrosis (CF) treatments. And these products help Vertex generate billions of dollars in annual revenue and profit. The stock also has rewarded investors with a gain of more than 120% over the past five years.

Let's turn to a smaller biotech that Vertex knows very well: CRISPR Therapeutics (NASDAQ: CRSP). The two companies are partners in a blood disorders program and recently submitted their treatment candidate for regulatory approval. If they win a nod, CRISPR may enter a big phase of growth.

But could CRISPR become the next Vertex? Let's find out.

Continue reading

Source Fool.com